cbdMD (NYSEAMERICAN:YCBD) had its price objective lowered by Benchmark from $9.00 to $7.00 in a research note released on Thursday, BenzingaRatingsTable reports. Benchmark currently has a speculative buy rating on the stock.
Separately, Cantor Fitzgerald started coverage on cbdMD in a research note on Thursday, November 7th. They set a neutral rating on the stock.
cbdMD stock opened at $2.95 on Thursday. cbdMD has a fifty-two week low of $2.54 and a fifty-two week high of $7.24.
cbdMD Company Profile
cbdMD, Inc produces and distributes various cannibidiol (CBD) products in the United States. It operates through three segments: Products, Licensing, and Entertainment. The Products segment produces and markets CBD tinctures, capsules, gummies, bath bombs, vape oils, topical creams, and animal treats and oils under the cdbMD brand.
Featured Article: How accurate is the Rule of 72?
Receive News & Ratings for cbdMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for cbdMD and related companies with MarketBeat.com's FREE daily email newsletter.